Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma Journal Article

   

Authors:	Gillis, M. C.; Weir, V. R.; Lezcano, C.; Iyer, G.; Gordon, A.
Article Title:	Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma
Keywords:	clinical article; human tissue; aged; prednisone; case report; drug dose reduction; drug withdrawal; skin toxicity; paraaortic lymph node; metastasis; drug eruption; multiple cycle treatment; punch biopsy; loading drug dose; pruritus; rash; evening dosage; fluorodeoxyglucose f 18; erythema; lymphocytic infiltration; transitional cell carcinoma; lymphadenopathy; pregabalin; betamethasone dipropionate; sulfadiazine silver; drug rechallenge; human; male; article; pembrolizumab; oncodermatology; supraclavicular lymph node; enfortumab vedotin; bullous; dupilumab; flexural
Journal Title:	JAAD Case Reports
Volume:	56
ISSN:	2352-5126
Publisher:	Elsevier Inc.
Date Published:	2025-02-01
Start Page:	40
End Page:	44
Language:	English
DOI:	10.1016/j.jdcr.2024.10.019
PROVIDER:	scopus
PMCID:	PMC11750431
PUBMED:	39839459
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85213492913&doi=10.1016%2fj.jdcr.2024.10.019&partnerID=40&md5=7d345ff233af7ccebab8490b742f843b
Notes:	Article -- MSK corresponding author is Allison Gordon -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/222190